株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品有力企業シリーズ:抗菌薬メーカー上位20社

Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022

発行 Visiongain Ltd 商品コード 247785
出版日 ページ情報 英文 185 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.80円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品有力企業シリーズ:抗菌薬メーカー上位20社 Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
出版日: 2012年06月21日 ページ情報: 英文 185 Pages
概要

当レポートでは、医薬品の卸売および流通産業に注目し、そこに活躍する上位企業20社のプロフィールおよび市場環境を探るとともに、将来の全世界、米国、欧州、日本における事業の収益やトレンドを探る市場調査データをまとめ、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

  • 有力抗菌薬メーカー:判明点の概要
  • 章別内容紹介
  • 調査・分析方法
  • 当レポートの対象範囲
  • 当レポートで使用する用語

第2章 抗菌薬市場イントロダクション

  • 細菌感染と抗菌薬
  • 薬剤市場
  • 抗菌薬市場:全体収益予測
  • 有力抗菌薬メーカー

第3章 米国の有力大手医薬品・抗菌薬メーカー

  • Pfizer
  • Merck & Co.
  • J&J
  • Abbott Laboratories

第4章 欧州の有力大手医薬品・抗菌薬メーカー

  • GSK
  • Novartis
  • Bayer
  • AstraZeneca
  • Roche

第5章 日本の有力医薬品・抗菌薬メーカー

  • 第一三共株式会社
  • 塩野義製薬株式会社
  • Meiji Seika ファルマ株式会社
  • アステラス製薬株式会社
  • 大日本住友製薬株式会社

第6章 有力抗菌薬専門メーカー

  • Cubist Pharmaceuticals
  • Medicis
  • Salix Pharmaceuticals
  • ViroPharma
  • Warner Chilcott
  • Allergan

第7章 新興抗菌薬メーカー

  • パイプライン企業
  • Durata Therapeutics
  • Optimer Pharmaceuticals
  • Rib-X Pharmaceuticals
  • Trius Therapeutics

第8章 結論

  • 抗菌薬市場を支配する大手医薬品メーカー
  • ジェネリック薬の台頭
  • 今後、小規模企業が産業や市場に強い影響力を及ぼすことも
目次

Antibacterial medicines - discover performance and commercial prospects of companies

How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers.

See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022.

In our study you find analytical profiles for leading antibiotics producers. The work shows product ranges, R&D and sales prospects, with revenue forecasts from 2012 to 2022:

  • Pfizer
  • GSK
  • Merck & Co.
  • Novartis
  • Bayer
  • J&J
  • Cubist Pharmaceuticals
  • AstraZeneca
  • Abbott Laboratories
  • Medicis
  • Coverage of 10 other leading manufacturers and four top emerging companies.

You see how antibacterial drug producers compare, discovering how they can compete from 2012. You also find out what will stimulate and restrain business for companies.

The report covers leading pharmaceutical players, specialty companies and emerging organisations. Also, you find companies grouped by region of origin:

  • The US
  • Europe
  • Japan.

Our investigation gives you business research and analysis, including revenue forecasts at world market, submarket and company level to 2022. You find commercial data, predictions, and analyses for leading organisations, their industry and their market area.

Antibacterial drug producers: commercial outlook from 2012

Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting C. difficile and MRSA infections will make a difference to 2022.

Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.

What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.

In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.

Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.

Company analyses, revenue forecasts, R&D and discussions of industry prospects

In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.

Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

  • Assess 20 leading antibacterial drug manufacturers, discovering their activities and outlooks from 2012
  • Discover overall world market and submarket revenue forecasts to 2022
  • Receive analyses of leading companies, seeing revenue forecasts to 2022
  • View a comparative analysis of trends among antibacterial manufacturers
  • Find existing revenues and operational data for leading companies
  • Review pipeline developments, assessing R&D trends and potential
  • Analyse recent licensing deals and acquisitions
  • Investigate competition and opportunities influencing sales
  • Review prospects for emerging companies and antimicrobial specialists
  • Find out what will stimulate and restrain the industry and market from 2012.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Gain research and analysis on antibacterial drug producers now

Our study is for everybody needing industry and market analyses of antibacterial drug developers and manufacturers. You find data, trends and predictions there. Please order that report now.

Table of Contents

1. Executive Summary

  • 1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods
  • 1.4 Scope of this Report
    • 1.4.1 Drugs Considered for this Report
      • 1.4.1.1 Ophthalmic and Dermatologic Antibacterials
    • 1.4.2 The Chinese Antibacterial Drugs Market
  • 1.5 Terminology Used in this Report

2. An Introduction to the Antibacterial Drugs Market

  • 2.1 Bacterial Infections and Antibacterial Drugs
    • 2.1.1 Gram-Positive and Gram-Negative Infections
    • 2.1.2 Treating Bacterial Infections
  • 2.2 The Antibacterial Drugs Market 2011
    • 2.2.1 Leading Classes of Antibacterial Drug
      • 2.2.1.1 Cephalosporins
      • 2.2.1.2 Penicillins
      • 2.2.1.3 Fluoroquinolones
      • 2.2.1.4 Macrolides
      • 2.2.1.5 Carbapenems
  • 2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
    • 2.3.1 Market Drivers 2012-2022
    • 2.3.2 Market Restraints 2012-2022
  • 2.4 Leading Antibacterial Drug Manufacturers in 2011
    • 2.4.1 Company Comparison
      • 2.4.1.1 Broad Product Portfolios
      • 2.4.1.2 Regional Focus
      • 2.4.1.3 Future of the Antibacterial Drugs Industry

3. The Leading US Big Pharma Antibacterial Drug Manufacturers 2012-2022

  • 3.1 Pfizer
    • 3.1.1 A Long History in Antibacterials
    • 3.1.2 Antibacterial Product Portfolio
      • 3.1.2.1 Dalacin (Clindamycin)
      • 3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)
      • 3.1.2.3 Tygacil (Tigecycline)
      • 3.1.2.4 Unasyn (Ampicillin/Sulbactam)
      • 3.1.2.5 Zithromax (Azithromycin)
      • 3.1.2.6 Zosyn (Piperacillin/Tazobactam)
      • 3.1.2.7 Zyvox (Linezolid)
    • 3.1.3 Antibacterial Revenue 2011
    • 3.1.4 Pipeline
      • 3.1.4.1 Pipeline 2007-2010
      • 3.1.4.2 PNU-100480 (Sutezolid)
    • 3.1.5 Pfizer Antibacterials: SWOT Analysis
    • 3.1.6 Antibacterial Revenue Forecast 2012-2022
  • 3.2 Merck & Co.
    • 3.2.1 Antibacterial Product Portfolio
      • 3.2.1.1 Avelox (Moxifloxacin)
      • 3.2.1.2 Invanz (Ertapenem)
      • 3.2.1.3 Primaxin (Imipenem/Cilastatin)
    • 3.2.2 Antibacterial Revenue 2011
    • 3.2.3 Recent Licensing Deals
    • 3.2.4 Pipeline
      • 3.2.4.1 MK-3415A
      • 3.2.4.2 MK-7655
    • 3.2.5 Merck Antibacterials: SWOT Analysis
    • 3.2.6 Antibacterial Revenue Forecast 2012-2022
  • 3.3 J&J
    • 3.3.1 Antibacterial Product Portfolio
      • 3.3.1.1 Doribax (Doripenem)
      • 3.3.1.2 Levaquin (Levofloxacin)
    • 3.3.2 Antibacterial Revenue 2011
      • 3.3.2.1 Patent Challenges
    • 3.3.3 Decreasing Investment in Antibacterials
    • 3.3.4 Pipeline: TMC207
    • 3.3.5 J&J Antibacterials: SWOT Analysis
    • 3.3.6 Antibacterial Revenue Forecast 2012-2022
  • 3.4 Abbott Laboratories
    • 3.4.1 Antibacterial Product Portfolio
    • 3.4.1.1 Biaxin (Clarithromycin)
    • 3.4.2 Antibacterial Revenue 2011
    • 3.4.3 Abbott Antibacterials: SWOT Analysis
    • 3.4.4 Antibacterial Revenue Forecast 2012-2022

4. The Leading European Big Pharma Antibacterial Drug Manufacturers 2012-2022

  • 4.1 GSK
    • 4.1.1 Antibacterial Product Portfolio
      • 4.1.1.1 Augmentin (Amoxicillin/Clavulanate)
      • 4.1.1.2 Bactroban (Mupirocin)
      • 4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)
      • 4.1.1.4 Fortum (Ceftazidime)
      • 4.1.1.5 Zinnat (Cefuroxime)
    • 4.1.2 Antibacterial Revenue 2011
    • 4.1.3 Antibacterials in the US
    • 4.1.4 Pipeline
      • 4.1.4.1 GSK2251052
      • 4.1.4.2 GSK1322322
    • 4.1.5 GSK Antibacterials: SWOT Analysis
    • 4.1.6 Antibacterial Revenue Forecast 2012-2022
  • 4.2 Novartis
    • 4.2.1 Antibacterial Product Portfolio
      • 4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)
      • 4.2.1.2 Cubicin (Daptomycin)
      • 4.2.1.3 Moxeza (Moxifloxacin)
      • 4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)
      • 4.2.1.5 Vigamox (Moxifloxacin)
    • 4.2.2 Antibacterial Revenue 2011
    • 4.2.3 Entering and Exiting Licensing Agreements
    • 4.2.4 Pipeline
      • 4.2.4.1 Finafloxacin
      • 4.2.4.2 LFF571
    • 4.2.5 Novartis Antibacterials: SWOT Analysis
    • 4.2.6 Antibacterial Revenue Forecast 2012-2022
  • 4.3 Bayer
    • 4.3.1 Antibacterial Product Portfolio
      • 4.3.1.1 Avelox (Moxifloxacin)
      • 4.3.1.2 Cipro (Ciprofloxacin)
    • 4.3.2 Antibacterial Revenue 2011
    • 4.3.3 Avelox Patent Challenges
    • 4.3.4 Bayer and Trius Therapeutics
    • 4.3.5 Pipeline
      • 4.3.5.1 Ciprofloxacin Inhale
      • 4.3.5.2 Amikacin Inhale
    • 4.3.6 Bayer Antibacterials: SWOT Analysis
    • 4.3.7 Antibacterial Revenue Forecast 2012-2022
  • 4.4 AstraZeneca
    • 4.4.1 Antibacterial Product Portfolio
      • 4.4.1.1 Cubicin (Daptomycin)
      • 4.4.1.2 Merrem (Meropenem)
      • 4.4.1.3 Zinforo (Ceftaroline)
    • 4.4.2 Antibacterial Revenue 2011
    • 4.4.3 AstraZeneca Acquires Novexel
    • 4.4.4 Pipeline
      • 4.4.4.1 CAZ-AVI
      • 4.4.4.2 CEF104
      • 4.4.4.3 NXL103
      • 4.4.4.4 AZD5847
    • 4.4.5 AstraZeneca Antibacterials: SWOT Analysis
    • 4.4.6 Antibacterial Revenue Forecast 2012-2022
  • 4.5 Roche
    • 4.5.1 Antibacterial Product Portfolio
      • 4.5.1.1 Rocephin (Ceftriaxone)
    • 4.5.2 Antibacterial Revenue 2011
    • 4.5.3 Roche Antibacterials: SWOT Analysis
    • 4.5.4 Antibacterial Revenue Forecast 2012-2022

5. The Leading Japanese Antibacterial Drug Manufacturers 2012-2022

  • 5.1 Daiichi Sankyo
    • 5.1.1 Antibacterial Product Portfolio
      • 5.1.1.1 Cravit (Levofloxacin)
    • 5.1.2 Antibacterial Revenue 2011
    • 5.1.3 Lifecycle Management
    • 5.1.4 Pipeline
    • 5.1.5 Daiichi Sankyo Antibacterials: SWOT Analysis
    • 5.1.6 Antibacterial Revenue Forecast 2012-2022
  • 5.2 Shionogi & Co
    • 5.2.1 Antibacterial Product Portfolio
      • 5.2.1.1 Finibax (Doripenem)
      • 5.2.1.2 Flomox (Cefcapene)
      • 5.2.1.3 Shionogi Acquires Victory Pharma's Portfolio
    • 5.2.2 Antibacterial Revenue 2011
    • 5.2.3 Lifecycle Management
    • 5.2.4 Patent Challenges
    • 5.2.5 Pipeline
      • 5.2.5.1 S-649266
    • 5.2.6 Shionogi Antibacterials: SWOT Analysis
    • 5.2.7 Antibacterial Revenue Forecast 2012-2022
  • 5.3 Meiji Seika Pharma
    • 5.3.1 Antibacterial Product Portfolio
      • 5.3.1.1 Meiact (Cefditoren)
    • 5.3.2 Antibacterial Revenue 2011
    • 5.3.3 Generic Competition
    • 5.3.4 ME1071
    • 5.3.5 Meiji Seika Pharma Antibacterials: SWOT Analysis
    • 5.3.6 Antibacterial Revenue Forecast 2012-2022
  • 5.4 Astellas Pharma
    • 5.4.1 Antibacterial Product Portfolio
      • 5.4.1.1 Cefzon (Cefdinir)
      • 5.4.1.2 Geninax (Garenoxacin)
    • 5.4.2 Antibacterial Revenue 2011
    • 5.4.3 Astellas and Optimer Pharmaceuticals
    • 5.4.4 Astellas and Theravance
    • 5.4.5 Astellas Pharma Antibacterials: SWOT Analysis
    • 5.4.6 Antibacterial Revenue Forecast 2012-2022
  • 5.5 Dainippon Sumitomo Pharma
    • 5.5.1 Meropen (Meropenem)
    • 5.5.2 Antibacterial Revenue 2011
    • 5.5.3 Licensing Deals
    • 5.5.4 Pipeline
    • 5.5.4.1 DSP-5990
    • 5.5.5 Dainippon Sumitomo Antibacterials: SWOT Analysis
    • 5.5.6 Antibacterial Revenue Forecast 2012-2022

6. The Leading Specialist Antibacterial Drug Manufacturers 2012-2022

  • 6.1 Cubist Pharmaceuticals
    • 6.1.1 Antibacterial Product Portfolio
      • 6.1.1.1 Cubicin (Daptomycin)
    • 6.1.2 Antibacterial Revenue 2011
    • 6.1.3 Lifecycle Management
    • 6.1.4 Patent Challenges
    • 6.1.5 Pipeline
      • 6.1.5.1 CXA-201
      • 6.1.5.2 CB-315
    • 6.1.6 Cubist Antibacterials: SWOT Analysis
    • 6.1.7 Antibacterial Revenue Forecast 2012-2022
  • 6.2 Medicis
    • 6.2.1 Antibacterial Product Portfolio
      • 6.2.1.1 Solodyn (Minocycline)
      • 6.2.1.2 Ziana (Clindamycin/Tretinoin)
    • 6.2.2 Antibacterial Revenue 2011
    • 6.2.3 Patent Extensions and Challenges
    • 6.2.4 Pipeline
      • 6.2.4.1 GW05
    • 6.2.5 Medicis Antibacterials: SWOT Analysis
    • 6.2.6 Antibacterial Revenue Forecast 2012-2022
  • 6.3 Salix Pharmaceuticals
    • 6.3.1 Xifaxan (Rifamixin)
    • 6.3.2 Antibacterial Revenue 2011
    • 6.3.3 Expanding Approved Indications
    • 6.3.4 Salix Pharmaceuticals Antibacterials: SWOT Analysis
    • 6.3.5 Antibacterial Revenue Forecast 2012-2022
  • 6.4 ViroPharma
    • 6.4.1 Vancocin (Vancomycin)
    • 6.4.2 Antibacterial Revenue 2011
    • 6.4.3 Generic Competition
    • 6.4.4 Pipeline: VP20621
    • 6.4.5 ViroPharma Antibacterials: SWOT Analysis
    • 6.4.6 Antibacterial Revenue Forecast 2012-2022
  • 6.5 Warner Chilcott
    • 6.5.1 Doryx (Doxycycline)
    • 6.5.2 Antibacterial Revenue 2011
    • 6.5.3 Patent Challenges
    • 6.5.4 Pipeline
    • 6.5.5 Warner Chilcott Antibacterials: SWOT Analysis
    • 6.5.6 Antibacterial Revenue Forecast 2012-2022
  • 6.6 Allergan
    • 6.6.1 Antibacterial Product Portfolio
      • 6.6.1.1 Zymar (Gatifloxacin)
      • 6.6.1.2 Zymaxid (Gatifloxacin)
    • 6.6.2 Antibacterial Revenue 2011
    • 6.6.3 Patent Challenges
    • 6.6.4 Allergan Antibacterials: SWOT Analysis
    • 6.6.5 Antibacterial Revenue Forecast 2012-2022

7. Emerging Antibacterial Manufacturers

  • 7.1 Pipeline Companies 2012
  • 7.2 Durata Therapeutics
    • 7.2.1 Future Outlook
  • 7.3 Optimer Pharmaceuticals
    • 7.3.1 Future Outlook
  • 7.4 Rib-X Pharmaceuticals
    • 7.4.1 Future Outlook
  • 7.5 Trius Therapeutics
  • 7.5.1 Future Outlook

8. Conclusions

  • 8.1 Big Pharma Dominated the Antibacterials Market in 2011
  • 8.2 The Rise of Generics
  • 8.3 Small Companies Can Have a Big Impact on the Industry and Market to 2022

List of Tables

  • Table 1.1 Currency Exchange Rates, 2011
  • Table 1.2 Common Abbreviations Used in this Report
  • Table 2.1 Classification of Common Infection-Causing Bacteria
  • Table 2.2 Antibacterial Drugs Market by Class, 2010-2011
  • Table 2.3 Selected Classes of Antibacterial Drug and their Mechanism of Action
  • Table 2.4 Cephalosporins: Role in the Antibacterial Drugs Market, 2011
  • Table 2.5 Penicillins: Role in the Antibacterial Drugs Market, 2011
  • Table 2.6 Fluoroquinolones: Role in the Antibacterial Drugs Market, 2011
  • Table 2.7 Macrolides: Role in the Antibacterial Drugs Market, 2011
  • Table 2.8 Carbapenems: Role in the Antibacterial Drugs Market, 2011
  • Table 2.9 Antibacterial Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022
  • Table 2.10 Top 20 Antibacterial Manufacturers by Revenue, 2011
  • Table 2.11 Antibacterial Revenue as a Share of Pharmaceutical Revenue, 2011
  • Table 3.1 Pfizer: Key Facts, 2012
  • Table 3.2 Pfizer: Antibacterial Revenue, 2009-2011
  • Table 3.3 Pfizer: Antibacterial SWOT Analysis, 2012-2022
  • Table 3.4 Pfizer: Antibacterial Revenue Forecast, 2011-2022
  • Table 3.5 Merck & Co: Key Facts, 2012
  • Table 3.6 Merck & Co: Antibacterial Revenue, 2009-2011
  • Table 3.7 Merck & Co: Antibacterial SWOT Analysis, 2012-2022
  • Table 3.8 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
  • Table 3.9 J&J: Key Facts, 2012
  • Table 3.10 J&J: Antibacterial Revenue, 2009-2011
  • Table 3.11 J&J: Antibacterial SWOT Analysis, 2012-2022
  • Table 3.12 J&J: Antibacterial Revenue Forecast, 2011-2022
  • Table 3.13 Abbott: Key Facts, 2012
  • Table 3.14 Abbott: Antibacterial SWOT Analysis, 2012-2022
  • Table 3.15 Abbott: Antibacterial Revenue Forecast, 2011-2022
  • Table 4.1 GSK: Key Facts, 2012
  • Table 4.2 GSK: Antibacterial Revenue, 2010-2011
  • Table 4.3 Augmentin, Revenue by Region, 2011
  • Table 4.4 GSK: Antibacterial Drug Pipeline, 2012
  • Table 4.5 GSK: Antibacterial SWOT Analysis, 2012-2022
  • Table 4.6 GSK: Antibacterial Revenue Forecast, 2011-2022
  • Table 4.7 Novartis: Key Facts, 2012
  • Table 4.8 Novartis: Antibacterial Revenue, 2009-2011
  • Table 4.9 Novartis: Antibacterial SWOT Analysis, 2012-2022
  • Table 4.10 Novartis: Antibacterial Revenue Forecast, 2011-2022
  • Table 4.11 Bayer: Key Facts, 2012
  • Table 4.12 Bayer: Antibacterial Revenue, 2009-2011
  • Table 4.13 Avelox: Patent Expiries by Country, 2013-2015
  • Table 4.14 Bayer: Antibacterial SWOT Analysis, 2012-2022
  • Table 4.15 Bayer: Antibacterial Revenue Forecast, 2011-2022
  • Table 4.16 AstraZeneca: Key Facts, 2012
  • Table 4.17 AstraZeneca: Antibacterial Revenue, 2008-2011
  • Table 4.18 AstraZeneca: Antibacterial SWOT Analysis, 2012-2022
  • Table 4.19 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
  • Table 4.20 Roche: Key Facts, 2012
  • Table 4.21 Roche: Antibacterial Revenue, Q1-Q4 2011
  • Table 4.22 Roche: Antibacterial Revenue by Region, Q1 2012
  • Table 4.23 Roche: Antibacterial SWOT Analysis, 2012-2022
  • Table 4.24 Roche: Antibacterial Revenue Forecast, 2011-2022
  • Table 5.1 Daiichi Sankyo: Key Facts, 2012
  • Table 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
  • Table 5.3 Daiichi Sankyo: Antibacterial SWOT Analysis, 2012-2022
  • Table 5.4 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
  • Table 5.5 Shionogi: Key Facts, 2012
  • Table 5.6 Shionogi: Antibacterial SWOT Analysis, 2012-2022
  • Table 5.7 Shionogi: Antibacterial Revenue Forecast, 2011-2022
  • Table 5.8 Meiji Seika Pharma: Key Facts, 2012
  • Table 5.9 Meiji Seika Pharma: Antibacterial SWOT Analysis, 2012-2022
  • Table 5.10 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
  • Table 5.11 Astellas Pharma: Key Facts, 2012
  • Table 5.12 Astellas Pharma: Leading Antibacterial Drug Revenue, FY 2007-2011
  • Table 5.13 Astellas Pharma: Antibacterial SWOT Analysis, 2012-2022
  • Table 5.14 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
  • Table 5.15 Dainippon Sumitomo: Key Facts, 2012
  • Table 5.16 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
  • Table 5.17 Dainippon Sumitomo: Antibacterial SWOT Analysis, 2012-2022
  • Table 5.18 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
  • Table 6.1 Cubist Pharmaceuticals: Key Facts, 2012
  • Table 6.2 Cubist: Antibacterial Revenue, 2008-2011
  • Table 6.3 Cubicin: International Revenue Payments, 2008-2011
  • Table 6.4 Cubist: Antibacterial SWOT Analysis, 2012-2022
  • Table 6.5 Cubist: Antibacterial Revenue Forecast, 2011-2022
  • Table 6.6 Medicis: Key Facts, 2012
  • Table 6.7 Medicis: Antibacterial Revenue, 2009-2011
  • Table 6.8 Medicis: Antibacterial SWOT Analysis, 2012-2022
  • Table 6.9 Medicis: Antibacterial Revenue Forecast, 2011-2022
  • Table 6.10 Salix Pharmaceuticals: Key Facts, 2012
  • Table 6.11 Salix: Antibacterial Revenue, 2009-2011
  • Table 6.12 Salix: Antibacterial SWOT Analysis, 2012-2022
  • Table 6.13 Salix: Antibacterial Revenue Forecast, 2011-2022
  • Table 6.14 ViroPharma: Key Facts, 2012
  • Table 6.15 ViroPharma: Antibacterial Revenue, 2009-2011
  • Table 6.16 ViroPharma: Antibacterial SWOT Analysis, 2012-2022
  • Table 6.17 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
  • Table 6.18 Warner Chilcott: Key Facts, 2012
  • Table 6.19 Warner Chilcott: Antibacterial SWOT Analysis, 2012-2022
  • Table 6.20 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
  • Table 6.21 Allergan: Key Facts, 2012
  • Table 6.22 Allergan: Antibacterial SWOT Analysis, 2012-2022
  • Table 6.23 Allergan: Antibacterial Revenue Forecast, 2011-2022
  • Table 7.1 Emerging Companies in the Antibacterial Drugs Market, 2012
  • Table 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

List of Figures

  • Figure 2.1 Antibacterial Drugs Market by Class, 2010-2011
  • Figure 2.2 Antibacterial Drugs: Overall Market Forecast, 2011, 2016 & 2022
  • Figure 2.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022
  • Figure 2.4 Top 20 Antibacterial Manufacturers by Revenue, 2011
  • Figure 2.5 Antibacterial Drug Market Entry, 1935-2004
  • Figure 3.1 Pfizer: Antibacterial Market History, 1944-2009
  • Figure 3.2 Pfizer: Antibacterial Revenue Shares, 2011
  • Figure 3.3 Pfizer: Antibacterial Revenue Forecast, 2011-2022
  • Figure 3.4 Pfizer: Antibacterial Market Share, 2011-2022
  • Figure 3.5 Merck & Co: Antibacterial Revenue, 2009-2011
  • Figure 3.6 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
  • Figure 3.7 Merck & Co: Antibacterial Market Share, 2011-2022
  • Figure 3.8 J&J: Antibacterial Revenue, 2009-2011
  • Figure 3.9 J&J: Antibacterial Revenue Forecast, 2011-2022
  • Figure 3.10 J&J: Antibacterial Market Share, 2011-2022
  • Figure 3.11 Abbott: Antibacterial Revenue Forecast, 2011-2022
  • Figure 3.12 Abbott: Antibacterial Market Share, 2011-2022
  • Figure 4.1 GSK: Antibacterial Revenue Shares, 2011
  • Figure 4.2 Augmentin, Revenue Shares by Region, 2011
  • Figure 4.3 GSK: Antibacterial Revenue Forecast, 2011-2022
  • Figure 4.4 GSK: Antibacterial Market Share, 2011-2022
  • Figure 4.5 Novartis: Antibacterial Revenue Shares, 2011
  • Figure 4.6 Novartis: Antibacterial Revenue Forecast, 2011-2022
  • Figure 4.7 Novartis: Antibacterial Market Share, 2011-2022
  • Figure 4.8 Bayer: Antibacterial Revenue, 2009-2011
  • Figure 4.9 Bayer: Antibacterial Revenue Forecast, 2011-2022
  • Figure 4.10 Bayer: Antibacterial Market Share, 2011-2022
  • Figure 4.11 AstraZeneca: Antibacterial Sales Revenue, 2008-2011
  • Figure 4.12 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
  • Figure 4.13 AstraZeneca: Antibacterial Market Share, 2011-2022
  • Figure 4.14 Roche: Antibacterial Revenue Shares, Q1-Q4 2011
  • Figure 4.15 Roche: Antibacterial Revenue Shares by Region, Q1 2012
  • Figure 4.16 Roche: Antibacterial Revenue Forecast, 2011-2022
  • Figure 4.17 Roche: Antibacterial Market Share, 2011-2022
  • Figure 5.1 Daiichi Sankyo: Antibacterial Market History, 1937-1993
  • Figure 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
  • Figure 5.3 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
  • Figure 5.4 Daiichi Sankyo: Antibacterial Market Share, 2011-2022
  • Figure 5.5 Shionogi: Antibacterial Revenue Forecast, 2011-2022
  • Figure 5.6 Shionogi: Antibacterial Market Share, 2011-2022
  • Figure 5.7 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
  • Figure 5.8 Meiji Seika Pharma: Antibacterial Market Share, 2011-2022
  • Figure 5.9 Astellas Pharma: Leading Antibacterial Drug Revenues, FY 2007-2011
  • Figure 5.10 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
  • Figure 5.11 Astellas Pharma: Antibacterial Market Share, 2011-2022
  • Figure 5.12 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
  • Figure 5.13 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
  • Figure 5.14 Dainippon Sumitomo: Antibacterial Market Share, 2011-2022
  • Figure 6.1 Cubist: Antibacterial Revenue, 2008-2011
  • Figure 6.2 Cubicin: International Revenue Payments, 2008-2011
  • Figure 6.3 Cubist: Antibacterial Market Share, 2011-2022
  • Figure 6.4 Cubist: Antibacterial Revenue Forecast, 2011-2022
  • Figure 6.5 Medicis: Antibacterial Revenue, 2009-2011
  • Figure 6.6 Medicis: Antibacterial Revenue Forecast, 2011-2022
  • Figure 6.7 Medicis: Antibacterial Market Share, 2011-2022
  • Figure 6.8 Salix: Antibacterial Revenue, 2009-2011
  • Figure 6.9 Salix: Antibacterial Revenue Forecast, 2011-2022
  • Figure 6.10 Salix: Antibacterial Market Share, 2011-2022
  • Figure 6.11 ViroPharma: Antibacterial Revenue, 2009-2011
  • Figure 6.12 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
  • Figure 6.13 ViroPharma: Antibacterial Market Share, 2011-2022
  • Figure 6.14 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
  • Figure 6.15 Warner Chilcott: Antibacterial Market Share, 2011-2022
  • Figure 6.16 Allergan: Antibacterial Revenue Forecast, 2011-2022
  • Figure 6.17 Allergan: Antibacterial Market Share, 2011-2022
  • Figure 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

Companies Listed

  • Abbott Laboratories
  • Adolor (part of Cubist)
  • Advanced Life Sciences
  • AiCuris
  • Akorn
  • Alcon Laboratories (a division of Novartis)
  • Alfa Wassermann
  • Allergan
  • Anacor Pharmaceuticals
  • Apotex
  • Astellas Pharma
  • AstraZeneca
  • Barr Laboratories (part of Teva)
  • Basilea Pharmaceutica
  • Bayer
  • BioRelix
  • Biovail Laboratories (part of Valeant Pharmaceuticals)
  • Bristol-Myers Squibb
  • Calixa Therapeutics (part of Cubist)
  • Cempra Pharmaceuticals
  • Chiron (now part of Novartis)
  • Cornerstone Therapeutics
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • Daiichi Sankyo Pharmaceutical (Beijing)
  • Daiichi Sankyo Pharmaceutical (Shanghai)
  • Dainippon Pharmaceutical (part of Dainippon Sumitomo)
  • Dainippon Sumitomo Pharma
  • DAVA Pharmaceuticals
  • Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) [US]
  • Dr Reddy's Laboratories
  • Durata Therapeutics
  • Eli Lilly
  • EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA) [US]
  • Forest Laboratories
  • Fujisawa Pharmaceutical (part of Astellas Pharma)
  • Furiex Pharmaceuticals
  • Genzyme (part of Sanofi)
  • Graceway Pharmaceuticals
  • GSK
  • Heritage Pharmaceuticals
  • Hikma Farmaceutica
  • Hi-Tech Pharmacal
  • Hospira
  • Impax Laboratories
  • Innovative Medicines Initiative [EU]
  • Itochu Chemical Frontier
  • Janssen Pharmaceutica (a subsidiary of J&J)
  • Japan Patent Office (JPO)
  • Johnson & Johnson (J&J)
  • Kyorin Pharmaceutical
  • Lupin
  • Massachusetts Biologic Laboratories
  • Mayne Pharma
  • Medarex (part of Bristol-Myers Squibb)
  • Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
  • Medicis
  • Medison Pharma
  • Meiji Holdings (parent company of Meiji Seika Pharma)
  • Meiji Seika Pharma
  • Merck & Co.
  • MerLion Pharmaceuticals
  • Ministry of Health, Labor and Welfare (MHLW)
  • Mylan
  • Mylan Seiyaku (a subsidiary of Mylan)
  • Nabriva Therapeutics
  • Nanotherapeutics
  • National Institute of Allergy and Infectious Diseases (NIAID) [US]
  • Nektar Therapeutics
  • Nestle
  • NeuTec Pharma (part of Novartis, now closed)
  • Nichi-Iko Pharmaceutical
  • Nipro Pharma
  • Novartis
  • Novexel (part of AstraZeneca)
  • Optimer Biotechnology (a subsidiary of Optimer)
  • Optimer Pharmaceuticals
  • Ortho-McNeil Pharmaceutical (a subsidiary of J&J)
  • Paratek Pharmaceuticals
  • Patent and Trademark Office [US]
  • Peninsula Pharmaceuticals (part of J&J)
  • Pfizer
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmacia (part of Pfizer)
  • Pliva (part of Teva)
  • Proctor & Gamble (P&G)
  • Protez Pharmaceuticals (part of Novartis, now closed)
  • Ranbaxy (part of Daiichi Sankyo)
  • Rib-X Pharmaceuticals
  • Roche
  • Rutgers University [US]
  • Salix Pharmaceuticals
  • Sandoz (a division of Novartis)
  • Sanofi
  • Sawai Pharmaceutical
  • Schering-Plough (part of Merck & Co)
  • Scottish Medicines Consortium (SMC)
  • Senju Pharmaceutical
  • Sequella
  • Shantou Meiji Pharmaceuticals (a subsidiary of Meiji Seika Pharma)
  • Shionogi & Co
  • Simcere Pharmaceutical Group
  • State Food and Drug Administration (SFDA) [China]
  • Stiefel Laboratories (part of GSK)
  • Strides Arcolab
  • Sumitomo Pharmaceutical (part of Dainippon Sumitomo)
  • Sunovion Pharmaceuticals
  • TaiGen Biotechnology
  • Taisho Pharmaceutical
  • Taiyo Yakuhin (Taiyo Pharmaceutical Industry)
  • Takeda Pharmaceutical
  • TB Alliance
  • Tedec-Meiji Farma (a subsidiary of Meiji Seika Pharma)
  • Tetraphase Pharmaceuticals
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • Theravance
  • Tibotec Pharmaceuticals (part of Janssen Pharmaceutica)
  • Towa Pharmaceutical
  • Toyama Chemical
  • Trius Therapeutics
  • Upjohn (part of Pfizer)
  • Victory Pharma
  • Vicuron Pharmaceuticals (part of Durata)
  • ViroPharma
  • Wakunaga Pharmaceutical
  • Warner Chilcott
  • Warner Lambert (part of Pfizer)
  • Watson Pharmaceuticals
  • Women First HealthCare
  • World Health Organization (WHO)
  • Wyeth Pharmaceuticals (part of Pfizer)
  • Yale University [US]
  • Yamanouchi Pharmaceutical (part of Astellas)
  • Zuellig Pharma
Back to Top